Clinical Trials | Phase 1/2a, Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients with Advanced Prostate Cancer

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have advanced prostate cancer. If you join this study, you will receive an investigational drug, PRL-02. The main purpose of this study is to test PRL-02 to find out which is the best dose to use in future research studies. The study also aims to assess the safety of PRL-02, how it is absorbed by and cleared from the body, and how well it works against prostate cancer. Everyone who takes part will be treated with PRL-02 in combination with prednisone or dexamethasone. Recruitment and treatment with the study medication is expected to last up to approximately three years. After that, there is a follow-up period of one month. This means you could keep seeing the Study Doctor for approximately three years, if you participate on this study. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04729114 [email protected]